HAEM5:ALK-negative anaplastic large cell lymphoma: Difference between revisions
| [pending revision] | [pending revision] |
| Line 501: | Line 501: | ||
|No | |No | ||
|Not seen in PTCL-NOS<ref name=":2" /> or ALK+ ALCL<ref name=":2" /><ref name=":6" /> | |Not seen in PTCL-NOS<ref name=":2" /> or ALK+ ALCL<ref name=":2" /><ref name=":6" /> | ||
* Ruxolitinib may be used to target JAK-STAT pathway (not FDA-approved) | |||
|- | |- | ||
|''JAK1'' | |''JAK1'' | ||